NDA 021667 · Emmaus Medcl
Nutrestore
L-Glutamine · Oral
NovelOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 31, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jun 10, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
150
32 Phase 3, 9 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NUTRESTORE · L-GLUTAMINE 5GM/PACKET · FOR SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "L-Glutamine" as an intervention, any sponsor and status, largest first.
- Glutamine Supplementation to Prevent Death or Infection in Extremely Premature InfantsPivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT00005775 · 1,433 participants · Start Jul 1999 · Primary completion Dec 2000
Drug: Glutamine; Placebo · For: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age and 2 more
Sites: Birmingham, Alabama; Palo Alto, California; San Diego, California · 15 sites in all
- Scandinavian Intensive Care Unit (ICU) Glutamine StudyPivotal-lookingTerminated
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT00922714 · 1,000 participants (planned) · Start Oct 2003 · Primary completion May 2007
Drug: Glutamine; saline (placebo) · For: ICU Patients
Sites: Stockholm, Sweden
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Calithera Biosciences, IncIndustry
NCT03428217 · 444 participants · Start Apr 24, 2018 · Primary completion Aug 31, 2020
Drug: CB-839; Cabozantinib and 1 more · For: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 133 sites in all
- Long-term Impact and Intervention for Diarrhea in BrazilPivotal-lookingStatus unknown
University of VirginiaAcademic, hospital or other
NCT00133406 · 321 participants (planned) · Start Jun 2006 · Primary completion Dec 2011
Drug: Glutamine; Vitamin A and 2 more · For: Diarrheal Disorder
Sites: Fortaleza, Brazil
- The CRISIS Prevention StudyPivotal-lookingTerminated
Michael DeanAcademic, hospital or other
NCT00395161 · 293 participants · Start Apr 2007 · Primary completion Nov 2009
Drug: Metoclopramide; Zinc and 1 more · For: Sepsis
Sites: Little Rock, Arkansas; Los Angeles, California; Washington D.C., District of Columbia · 7 sites in all
- Safety, Tolerability, and Efficacy of AXA1125 in NASH With FibrosisPivotal-lookingStatus unknown
Axcella Health, IncIndustry
NCT04880187 · 273 participants (planned) · Start May 7, 2021 · Primary completion Sep 2023
Drug: AXA1125; Placebo · For: Non Alcoholic Steatohepatitis (NASH)
Sites: Cullman, Alabama; Tucson, Arizona; Canoga Park, California · 75 sites in all
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)Pivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT04305769 · 260 participants (planned) · Start Jun 1, 2021 · Primary completion Dec 31, 2026
Drug: Alanyl-glutamine · For: Clostridioides Difficile Infection; Clostridium Difficile Infection; Clostridium Difficile Diarrhea and 1 more
Sites: Charlottesville, Virginia; Roanoke, Virginia
Lynk Biotechnologies Pte LtdIndustry
NCT03743896 · 240 participants · Start May 18, 2016 · Primary completion Mar 10, 2017
Drug: Transdermal Glucosamine Cream · For: Osteoarthritis, Knee
Sites: Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Update on the treatment of chemotherapy and radiotherapy-induced buccal mucositis: a systematic review.
Wen S, Brito L, Santander J, et al. · Acta Odontol Latinoam 2023 · Systematic Review
- Multi-cohort analysis of depression-associated gut bacteria sheds insight on bacterial biomarkers across populations.
Liang S, Sin ZY, Yu J, et al. · Cell Mol Life Sci 2022 · Meta-Analysis
- Supplemental Protein and a Multinutrient Beverage Speed Wound Healing after Acute Sleep Restriction in Healthy Adults.
Smith TJ, Wilson M, Whitney C, et al. · J Nutr 2022 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Impact of preoperative beta-hydroxy-beta-methylbutyrate, arginine, and glutamine supplementation on inflammation in patients with cardiac surgery: A secondary analysis of a randomized controlled trial.
Ogawa M, Satomi-Kobayashi S, Yoshida N, et al. · J Cardiol 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of the recovery after heart surgery following preoperative supplementation with a combination of beta-hydroxy-beta-methylbutyrate, L-arginine, and L-glutamine: a double-blind randomized placebo-controlled clinical trial.
Norouzi M, Nadjarzadeh A, Maleki M, et al. · Trials 2022 · Randomized Controlled Trial
Sponsor: Emmaus Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.